Is the weight-loss drug boom moving past the Ozempic era?

Sales are booming for Novo Nordisk’s new weight loss pill.  In its first earnings report since the release of an alternative to its hit GLP-1 shot, Novo Nordisk’s outlook is looking a bit brighter. The company, which now makes Wegovy in pill form, raised its guidance for the year in light of the first quarter’s success.  Novo reported 1.3 million prescriptions for its weight loss pill, which is now available in the U.S., in the first quarter of 2026. The drugmaker plans to launch...